The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1339
Bioidentical Hormones
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

In recent years, many women have become concerned about the safety of pharmaceutical replacement hormones for treatment of menopausal symptoms. “Bioidentical” hormone preparations, which are not approved by the FDA, are heavily promoted in popular books and on TV as alternatives; these are derivatives of soy or plant extracts, chemically modified to be structurally identical to endogenous hormones. Most FDA-approved single-entity hormones are also derivatives of soy or plant extracts and are structurally identical to hormones produced by the ovary.1

MANUFACTURING STANDARDS — Bioidentical hormones are generally prepared in compounding pharmacies, which are not regulated by the FDA.2 The FDA has reported sub-potency, super-potency and contamination of pharmacy-compounded drugs. In one 2006 survey, their potency ranged from 67.5% to 268.4% of the amount specified on ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Bioidentical Hormones
Article code: 1339d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian